Policlinico S.Orsola-Malpighi-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2024

  1. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

    CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

  2. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

2023

  1. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study

    JHEP Reports, Vol. 5, Núm. 2

  2. Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial

    Journal of Clinical Oncology

2022

  1. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

2021

  1. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

    CardioVascular and Interventional Radiology, Vol. 44, Núm. 1, pp. 21-35

  2. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Núm. 5, pp. 1570-1584

2020

  1. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

    Hepatology, Vol. 72, Núm. 1, pp. 198-212

2019

  1. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 3, pp. 661-668

2018

  1. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 10, pp. 1721-1730

2017

  1. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres

    Annals of Surgical Oncology, Vol. 24, Núm. 9, pp. 2465-2473

2013

  1. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma

    Journal of Hepatology, Vol. 59, Núm. 4, pp. 753-761

2012

  1. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions

    Seminars in Liver Disease, Vol. 32, Núm. 4, pp. 348-359

2011

  1. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization

    Cancer Treatment Reviews, Vol. 37, Núm. 3, pp. 212-220

  2. Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation

    Hepatology, Vol. 54, Núm. 3, pp. 868-878

2010

  1. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma

    European Journal of Gastroenterology and Hepatology, Vol. 22, Núm. 4, pp. 391-398